Gyre Therapeutics (GYRE) Competitors $11.12 +1.13 (+11.31%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GYRE vs. VRNA, RYTM, MLTX, JANX, XENE, EWTX, MRUS, ACAD, TWST, and MORShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Twist Bioscience (TWST), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Xenon Pharmaceuticals Edgewise Therapeutics Merus ACADIA Pharmaceuticals Twist Bioscience MorphoSys Verona Pharma (NASDAQ:VRNA) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation. Do analysts prefer VRNA or GYRE? Verona Pharma currently has a consensus price target of $43.83, suggesting a potential upside of 5.22%. Given Verona Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Verona Pharma is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer VRNA or GYRE? In the previous week, Gyre Therapeutics had 2 more articles in the media than Verona Pharma. MarketBeat recorded 7 mentions for Gyre Therapeutics and 5 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.06 beat Gyre Therapeutics' score of 0.90 indicating that Verona Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VRNA or GYRE? 85.9% of Verona Pharma shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 4.8% of Verona Pharma shares are held by insiders. Comparatively, 19.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor VRNA or GYRE? Verona Pharma received 323 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformVerona PharmaOutperform Votes32380.55% Underperform Votes7819.45%Gyre TherapeuticsN/AN/A Which has more risk and volatility, VRNA or GYRE? Verona Pharma has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Which has preferable valuation & earnings, VRNA or GYRE? Verona Pharma has higher earnings, but lower revenue than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma$5.62M595.86-$54.37M-$1.92-21.70Gyre Therapeutics$105.03M9.90-$92.93MN/AN/A Is VRNA or GYRE more profitable? Verona Pharma has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Verona Pharma's return on equity of -79.54% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verona PharmaN/A -79.54% -43.49% Gyre Therapeutics -84.57%-118.43%-71.97% SummaryVerona Pharma beats Gyre Therapeutics on 11 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04B$6.86B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E RatioN/A10.75130.2217.53Price / Sales9.90287.791,246.14139.51Price / Cash38.7556.6541.2337.95Price / Book61.785.394.884.92Net Income-$92.93M$152.04M$119.65M$225.78M7 Day Performance10.98%-4.32%16.62%-1.56%1 Month Performance-11.89%2.80%16.34%6.68%1 Year Performance-55.27%17.30%35.38%22.48% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.3745 of 5 stars$11.12+11.3%N/A-54.6%$1.04B$105.03M0.0040News CoverageVRNAVerona Pharma1.0815 of 5 stars$42.68+3.0%$43.83+2.7%+141.2%$3.47B$460,000.00-22.2730Positive NewsRYTMRhythm Pharmaceuticals4.1214 of 5 stars$55.25+0.0%$63.70+15.3%+20.3%$3.40B$77.43M-12.76140Positive NewsMLTXMoonLake Immunotherapeutics1.7963 of 5 stars$52.98+3.2%$79.88+50.8%-7.2%$3.39BN/A-40.842News CoverageJANXJanux Therapeutics3.6007 of 5 stars$61.56+0.7%$89.90+46.0%+474.8%$3.23B$13.05M-52.2330XENEXenon Pharmaceuticals2.7408 of 5 stars$41.31+3.1%$56.90+37.7%-0.3%$3.15B$9.43M-14.20251EWTXEdgewise Therapeutics2.8314 of 5 stars$32.69+18.4%$42.33+29.5%+313.9%$3.10BN/A-22.8560Analyst ForecastShort Interest ↓News CoverageGap UpHigh Trading VolumeMRUSMerus2.9438 of 5 stars$42.80-0.1%$85.64+100.1%+77.9%$2.93B$35.93M-10.8437ACADACADIA Pharmaceuticals3.9301 of 5 stars$17.34+0.5%$25.60+47.6%-39.1%$2.89B$726.44M22.13510TWSTTwist Bioscience3.0264 of 5 stars$48.43+2.0%$51.90+7.2%+39.8%$2.87B$312.97M-13.19990MORMorphoSys0.0818 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies Verona Pharma Competitors Rhythm Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Janux Therapeutics Competitors Xenon Pharmaceuticals Competitors Edgewise Therapeutics Competitors Merus Competitors ACADIA Pharmaceuticals Competitors Twist Bioscience Competitors MorphoSys Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GYRE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
